Banque Transatlantique SA Trims Stake in Zoetis Inc. $ZTS

Banque Transatlantique SA lessened its stake in shares of Zoetis Inc. (NYSE:ZTS) by 26.2% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 176,793 shares of the company’s stock after selling 62,912 shares during the period. Banque Transatlantique SA’s holdings in Zoetis were worth $22,240,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the stock. MidFirst Bank acquired a new position in shares of Zoetis in the fourth quarter valued at approximately $633,000. Pacer Advisors Inc. boosted its position in Zoetis by 18.3% during the fourth quarter. Pacer Advisors Inc. now owns 141,883 shares of the company’s stock worth $17,852,000 after acquiring an additional 21,964 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its stake in Zoetis by 3,311.3% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 158,250 shares of the company’s stock worth $19,912,000 after acquiring an additional 153,611 shares during the period. Strive Financial Group LLC purchased a new stake in Zoetis in the 4th quarter worth approximately $390,000. Finally, Beacon Pointe Advisors LLC raised its holdings in Zoetis by 3.6% in the 4th quarter. Beacon Pointe Advisors LLC now owns 9,525 shares of the company’s stock valued at $1,198,000 after acquiring an additional 327 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Key Stories Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis outperformed the market in the latest session, which may be supporting trading momentum for ZTS. Zoetis Surpasses Market Returns: Some Facts Worth Knowing
• Neutral Sentiment: Several firms, including Rosen, Kessler Topaz, and others, reiterated the July 27, 2026 lead-plaintiff deadline in the pending securities class action against Zoetis, keeping investor attention on the case. Kessler Topaz Announces Securities Fraud Class Action
• Neutral Sentiment: The lawsuit-related articles themselves do not add new operational details, but they extend the legal overhang and may keep pressure on ZTS shares if investors focus on possible litigation costs or management credibility concerns. Pomerantz Investor Alert

Zoetis Stock Up 1.9%

Shares of NYSE ZTS opened at $78.69 on Friday. The stock has a market capitalization of $32.99 billion, a PE ratio of 13.05, a P/E/G ratio of 1.20 and a beta of 0.75. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. The firm has a fifty day moving average of $93.83 and a 200-day moving average of $112.78. Zoetis Inc. has a 52-week low of $72.38 and a 52-week high of $161.77.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.30 billion. During the same period last year, the business posted $1.48 earnings per share. The company’s quarterly revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, analysts anticipate that Zoetis Inc. will post 6.88 EPS for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be paid a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s payout ratio is currently 35.16%.

Insider Activity

In other news, Director Frank A. Damelio bought 6,650 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The stock was acquired at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the acquisition, the director owned 21,458 shares of the company’s stock, valued at $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Michael B. Mccallister bought 3,000 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were acquired at an average cost of $77.76 per share, with a total value of $233,280.00. Following the transaction, the director owned 24,524 shares in the company, valued at approximately $1,906,986.24. This represents a 13.94% increase in their position. The SEC filing for this purchase provides additional information. Insiders have bought 11,650 shares of company stock valued at $886,384 in the last three months. Corporate insiders own 0.22% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. BTIG Research reissued a “buy” rating and set a $160.00 price target on shares of Zoetis in a research note on Thursday, February 26th. Stifel Nicolaus lowered their price objective on Zoetis from $105.00 to $95.00 and set a “hold” rating for the company in a research report on Friday, May 22nd. William Blair reiterated an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Wall Street Zen downgraded Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Finally, Leerink Partners reissued a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Six analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $133.92.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.